Clinical trial
Sequential Chemotherapy in Treating Patients With Residual Disease Following…
NCT00003733 · SmithKline Beecham, Industry · Unknown status
Key facts
| NCT number | NCT00003733 |
|---|---|
| Title | Sequential Chemotherapy in Treating Patients With Residual Disease Following Surgery for Stage IIB, Stage III, or Stage IV Ovarian Cancer |
| Official title | A Phase II Study of Sequential Carboplatin, Paclitaxel and Hycamtin in Patients With Previously Untreated Advanced Ovarian Cancer |
| Lead sponsor | SmithKline Beecham, Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer |
| Intervention type | Drug |
| Interventions | carboplatin, paclitaxel, topotecan hydrochloride |
| Enrollment | 40 |
| Start date | Dec 1, 1997 |
| First posted | Jun 9, 2004 |
| Last update posted | Sep 20, 2013 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: